scispace - formally typeset
L

Lee A. Albacker

Researcher at Foundation Medicine

Publications -  99
Citations -  5872

Lee A. Albacker is an academic researcher from Foundation Medicine. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 24, co-authored 75 publications receiving 4197 citations. Previous affiliations of Lee A. Albacker include Harvard University & Brigham Young University.

Papers
More filters
Journal ArticleDOI

Tissue expression of PD-L1 mediates peripheral T cell tolerance

TL;DR: Evidence is provided that PD-L 1 expression on parenchymal cells rather than hematopoietic cells protects against autoimmune diabetes and point to a novel role for PD-1–PD-L1 interactions in mediating tissue tolerance.
Journal ArticleDOI

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Ferdinandos Skoulidis, +69 more
- 17 May 2018 - 
TL;DR: Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets.
Journal ArticleDOI

Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity

TL;DR: It is shown in a mouse model that influenza infection acutely induced airway hyper-reactivity (AHR), a cardinal feature of asthma, independently of T helper type 2 (TH2) cells and adaptive immunity.
Journal ArticleDOI

Mechanisms and therapeutic implications of hypermutation in gliomas.

Mehdi Touat, +105 more
- 15 Apr 2020 - 
TL;DR: Results show that chemotherapy can drive the acquisition of hypermutated populations without promoting a response to PD-1 blockade and supports the diagnostic use of mutational burden and signatures in cancer.
Journal ArticleDOI

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.

TL;DR: The results indicate that PD-L1 expression and TMB may each inform the use of ICIs, point to different mechanisms by which PD- L1 expression regulates ICI responsiveness, and identify new opportunities for therapeutic development.